医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Toshiba Corporation Selects Affymetrix Axiom Platform for Its Newly Launched Genotyping Service in Japan

2014年12月01日 PM08:30
このエントリーをはてなブックマークに追加


 

SANTA CLARA, Calif.

Affymetrix (NASDAQ: AFFX) announces its Axiom® Genotyping Solution platform has been selected by Toshiba Corporation’s (TYO: 6502) Healthcare Company as the platform for its newly launched genotyping service. Affymetrix collaborated with Toshiba to custom design and manufacture the Japonica Array™, which is based on the Axiom platform. This array contains unique genetic content specifically optimized for the Japanese population. Toshiba has launched this genotyping service as of Dec. 1, 2014 for Japanese population genotyping studies primarily servicing universities, hospitals, and other research agencies and institutes.

“After reviewing various microarray technology providers, we selected Affymetrix’ Axiom platform for our genotyping service based on its high throughput capability, cost effectiveness, superior performance, and highly reproducible manufacturing process. The team at Affymetrix worked closely with our scientists in designing this array, which contains the genetic content developed as the result of the collaboration with Tohoku University. It was a pleasure collaborating with Affymetrix in the development of Japonica Array™,” said Satoshi Tsunakawa, Corporate Senior Vice President of Toshiba Corporation and President and CEO of Toshiba’s Healthcare Company.

“We are very pleased to support Toshiba in delivering high-quality and cost-effective genotyping service to enable Japanese researchers to better understand the genetic markers associated with diseases and response to therapy specific to the Japanese population,” said Frank Witney, CEO and President of Affymetrix. “Based on our long history of successful business in Japan, it is clear that Japanese customers have a strong appreciation for quality and expect superior performance and reproducibility. This is a key strength for Affymetrix and we are glad Toshiba holds these high standards as well. Working together, we look forward to expanding the value of genetic information for the Japanese population.”

Axiom Biobank Genotyping Solution is the platform of choice for leading population genotyping studies such as UK Biobank, Million Veteran Program, and others. To learn more about Axiom Genotyping Solution, visit www.affymetrix.com/axiombiobank.

PLEASE NOTE: The Affymetrix logo, Affymetrix, and Axiom are registered trademarks of Affymetrix, Inc. All other trademarks and product names are the property of their respective owners.

About Affymetrix

Affymetrix technologies enable multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level, facilitating the rapid translation of bench-top research into clinical and routine use for human health and wellness. The Company provides leadership and support, partnering with customers in pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and non-profit research institutes in their quest to use biology for a better world. More than 2,300 microarray systems have been shipped around the world and more than 65,000 peer-reviewed papers have been published citing Affymetrix technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, Ohio, San Diego, Vienna, and Singapore. The Company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe, Asia, and Latin America. For more information about Affymetrix, please visit www.affymetrix.com.

Forward-looking statements

All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,” “beliefs,” “hopes,” “intentions,” “strategies,” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2013, and other SEC reports for subsequent quarterly periods.

CONTACT

Media Contact:
Mindy Lee-Olsen, 408-731-5523
Vice
President, Marketing Services
mindy_lee-olsen@affymetrix.com
or
Investor
Contact:

Doug Farrell, 408-731-5285
Vice President,
Investor Relations
doug_farrell@affymetrix.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗